Payment overview · 2025
General Payments
$256.84
11 reported records · 7 companies
Healthcare provider profile · identity verified
Murray Brand, D. O.
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, PA · NPI 1124061221
Verified facts
What the public records show
CMS Open Payments records show Murray Brand, D. O. received $256.84 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.71 | 35.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.94 | 17.9% | 2 | 2025 |
| KVK-Tech, Inc. | Unresolved — no canonical attribution shown | $44.55 | 17.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.67 | 10.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.97 | 7.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.18 | 6.3% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $14.82 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $256.84 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.94 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $38.61 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.76 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.67 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 878 | 229 |
| Amlodipine Besylate | Amlodipine Besylate | 585 | 136 |
| Metoprolol Succinate | Metoprolol Succinate | 468 | 121 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 452 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 448 | 105 |
| Omeprazole | Omeprazole | 384 | 90 |
| Lisinopril | Lisinopril | 376 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 373 | 87 |
| Losartan Potassium | Losartan Potassium | 338 | 85 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 316 | 30 |
| Ezetimibe | Ezetimibe | 311 | 75 |
| Metformin Hcl | Metformin Hcl | 309 | 76 |
| Gabapentin | Gabapentin | 260 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 233 | 59 |
| Alprazolam | Alprazolam | 216 | 42 |
| Tramadol Hcl | Tramadol Hcl | 188 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 181 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 37 |
| Famotidine | Famotidine | 159 | 39 |
| Furosemide | Furosemide | 151 | 45 |
| Clonazepam | Clonazepam | 150 | 29 |
| Trazodone Hcl | Trazodone Hcl | 144 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 41 |
| Eliquis | Apixaban | 138 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 44 |
| Azithromycin | Azithromycin | 131 | 102 |
| Hydralazine Hcl | Hydralazine Hcl | 127 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 115 | 30 |
| Simvastatin | Simvastatin | 113 | 31 |
| Montelukast Sodium | Montelukast Sodium | 110 | 30 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 109 | 25 |
| Buspirone Hcl | Buspirone Hcl | 100 | 12 |
| Carvedilol | Carvedilol | 100 | 30 |
| Pregabalin | Pregabalin | 99 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 24 |
| Jardiance | Empagliflozin | 95 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 23 |
| Methylprednisolone | Methylprednisolone | 83 | 58 |
| Farxiga | Dapagliflozin Propanediol | 79 | 17 |
| Glipizide Er | Glipizide | 79 | 14 |
| Cephalexin | Cephalexin | 77 | 44 |
| Trulicity | Dulaglutide | 74 | 12 |
| Ozempic | Semaglutide | 73 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 15 |
| Allopurinol | Allopurinol | 68 | 17 |
| Potassium Chloride | Potassium Chloride | 68 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 66 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 16 |
| Baclofen | Baclofen | 63 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 24 |
| Mupirocin | Mupirocin | 62 | 21 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 61 | suppressed |
| Repaglinide | Repaglinide | 59 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 57 | 12 |
| Mirtazapine | Mirtazapine | 55 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | 15 |
| Glipizide | Glipizide | 50 | 12 |
| Lorazepam | Lorazepam | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 15 |
| Myrbetriq | Mirabegron | 49 | 12 |
| Nifedipine Er | Nifedipine | 49 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 48 | 11 |
| Ciclopirox | Ciclopirox Olamine | 48 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | suppressed |
| Finasteride | Finasteride | 48 | 15 |
| Prednisone | Prednisone | 48 | 28 |
| Azelastine Hcl | Azelastine Hcl | 46 | 20 |
| Lidocaine | Lidocaine | 45 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 32 |
| Meclizine Hcl | Meclizine Hcl | 44 | 16 |
| Topiramate | Topiramate | 44 | suppressed |
| Valsartan | Valsartan | 44 | 12 |
| Vascepa | Icosapent Ethyl | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 42 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 11 |
| Bumetanide | Bumetanide | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 38 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 11 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 11 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 16 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 19 |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 17 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Nystatin | Nystatin | 16 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | 11 |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Sure Comfort | Pen Needle, Diabetic | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.84 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, NURTEC ODT, NUZYRA, PAXLOVID, SUBLOCADE, VRAYLAR, ZAVZPRET, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error